9072 - Association of Depth of Target Lesion Response to Brigatinib With Outcomes in Patients With ALK Inhibitor-Naive ALK+ NSCLC in ALTA-1L

https://qr.page/g/1A9ZEZsMffK

  9075 - Brigatinib in Japanese patients (pts) with ALK+ NSCLC: Final results from the phase 2 J-ALTA trial

https://qr.page/g/DlxvClo7DL

  9099 - Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non–small cell lung cancer (mNSCLC): treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD

https://qr.page/g/5shOatUnqR0

  9108 - Molecular Analysis of Circulating Tumor DNA (ctDNA) in Patients (Pts) With EGFR Exon 20 Insertion–Positive (ex20ins+) Advanced NSCLC Treated With Mobocertinib

https://qr.page/g/5oZjAopcPdG

  9115 - Matching-Adjusted Indirect Comparison (MAIC) of Mobocertinib vs Amivantamab in Patients with Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

https://qr.page/g/4uAaB5BnqhE

For Healthcare Professionals Only
VV-MEDMAT-69119 / May 2022